Glenmark USA is named in multiple class actions and direct-action suits, brought by direct purchasers, end-payers, indirect purchasers, and private plaintiffs. The cases allege both drug-specific conspiracies and a broader conspiracy involving multiple generic drug manufacturers. Shares of Glenmark Pharmaceuticals Ltd ended at ₹2,020.30, down by ₹31.15, or 1.52%, on the BSE.
